(Q46052667)
Statements
An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer (English)
Carmel Pezaro
Mark A Rosenthal
Ian D Davis
Craig Underhill
Dusan Kotasek
Benjamin Solomon